SUNPHARMA

says working towards full regulatory resolution at 3 plants facing USFDA action

focuses on compliance across its manufacturing units. It aims for full regulatory resolution at facilities facing USFDA action. The company has completed CAPA implementation at Halol. CAPA implementation is in process at Mohali and Dadra. R&D investment is expected to be 6-8% of sales. The company anticipates mid to high single-digit consolidated topline growth in FY26.